Results 141 to 150 of about 387,442 (344)

A phenomap of TTR amyloidosis to aid diagnostic screening

ESC Heart Failure, Volume 12, Issue 2, Page 1113-1118, April 2025.
Abstract Cardiac amyloidosis due to transthyretin (ATTR) remains an underdiagnosed cause of cardiomyopathy. As awareness of the disease grows and referrals for ATTR increase, clinicians are likely to encounter more atypical forms of the condition in clinical practice.
Alexios S. Antonopoulos, Theodoros Tsampras, George Lazaros, Konstantinos Tsioufis, Charalambos Vlachopoulos   +4 more
wiley   +1 more source

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad, Jeanne du Fay de Lavallaz, Michael J. Zhang, Thanat Chaikijurajai, Bo Ye, Prabhjot S. Nijjar, Julie A. Lahiri, Cindy M. Martin, Tamas Alexy, Markus Meyer   +9 more
wiley   +1 more source

Understanding the Mechanisms of the Protective Effects of Caffeine in Cardiac Autonomic Neuropathy [PDF]

, 2019
Graduate ...
Madzinge, Vhuthuhawe T
core   +1 more source

RECENT DEVELOPMENTS IN ANAESTHESIA IN THE BRITISH ISLES WITH PARTICULAR REFERENCE TO INDUCED HYPOTENSION [PDF]

, 1954
I.W. Magill
openalex   +1 more source

Early in‐hospital treatment of acute heart failure. Part 2 of the international expert opinion series on AHF management

ESC Heart Failure, EarlyView.
This state‐of‐the‐art review outlines a practical, evidence‐based framework for early acute heart failure management to address critical gaps in current guidance and improve early treatment outcomes. Key components include early identification of co‐existing conditions, bedside haemodynamic profiling, a structured diagnostic approach incorporating both
Anika S. Naidu, Andrew P. Ambrosy, Gad Cotter, Edimar A. Bocchi, Javed Butler, Ovidiu Chioncel, Beth Davison, Anastase Dzudie, Yonathan Freund, Marat Fudim, Sivadasanpillai Harikrishnan, Ivna G. Cunha, Alexandre Mebazaa, Robert J. Mentz, Òscar Miró, Siti E. Nauli, Mateo Pagnesi, Naoki Sato, Gianluigi Savarese, Karen Sliwa‐Hahnle, Yuhui Zhang, Jingmin Zhou, Jan Biegus   +22 more
wiley   +1 more source

Phenotype characterization of heart failure with preserved ejection fraction in medical device and surgical trials

ESC Heart Failure, EarlyView.
This systematic review identified 24 clinical trials of medical device and surgical interventions for HFpEF, with 16 demonstrating at least safety and feasibility, but little evidence of long‐term benefit. Phenotype‐based responses suggest that certain interventions may benefit specific HFpEF subgroups, yet most trials suffered from heterogeneous ...
Kurdo Araz, Francesco Fioretti, Sara Ladak, Mohammed Obaidan, Javed Butler, Aamir Hameed   +5 more
wiley   +1 more source

Anaesthetic management of a pregnant women taking sildenafil for intra uterine growth retardation undergoing caesarean section: a case report.

Critical Care Innovations
The role of Sildenafil was found in the potential weight gain of the foetus in pregnant women with intrauterine growth retardation (IUGR). Sildenafil acted by inhibiting phosphodiesterase type 5 (PDE5), which was an important enzyme responsible for the ...
Sandeep Kumar, Sudhansu Sekhar Nayak, Usha Yadav, Rupesh Yadav   +3 more
doaj   +1 more source

THE FLUORIMETRIC ESTIMATION OF ADRENALINE AND NORADRENALINE DURING HAEMORRHAGIC HYPOTENSION

, 1958
R.A. MILLAR, B. G. Benfey
openalex   +1 more source

A novel treatment score (QUAD score) to promote treatment optimization in heart failure with a reduced ejection fraction

ESC Heart Failure, EarlyView.
The QUAD score was developed to promote adherence to clinical practice guidelines for patients with heart failure and a reduced left ventricular ejection fraction <50%. In newly diagnosed patients who had completed therapy titration, we found that patients with an excellent QUAD score had a significant reduction in the risk of mortality or ...
Henry Oluwasefunmi Savage, Jason N. Dungu, Anthony Dimarco, Brian Li, Samantha Langley, Jonathan Kojo Amoah, Paraic Cliffe, Archana Ganapathy, Peter Watters, Patricia Campbell, Nicola Melarkey, Simon Duckett, Sean Davies, Matthew Dewhurst, Karen Hann, Louise Clayton, Rhys Williams, Victoria Ruszala, Teresa Onwere‐Tan, Fozia Zahir Ahmed, Ibrahim Arosi, Kimberly Gray, Mark C. Petrie, John G.F. Cleland   +23 more
wiley   +1 more source

SGLT2 inhibitors for the prevention and treatment of heart failure: A scientific statement of the HFA and the HFAI

ESC Heart Failure, EarlyView.
Abstract In the 2021 European Society of Cardiology (ESC) heart failure (HF) guidelines, sodium–glucose cotransporter 2 (SGLT2) inhibitors were recommended for the prevention of HF in patients with type 2 diabetes mellitus (T2DM) and for the treatment of HF with reduced ejection fraction (HFrEF).
Marco Metra, Daniela Tomasoni, Marianna Adamo, Offer Amir, Stefan D. Anker, Antoni Bayes‐Genis, Michael Boehm, Javed Butler, Ovidiu Chioncel, Gerasimos Filippatos, Finn Gustafsson, Ewa A. Jankowska, Juan Carlos Kaski, Brenda Moura, Mark C. Petrie, Piotr Ponikowski, Amina Rakisheva, Arsen Ristic, Francois Roubille, Gianluigi Savarese, Petar Seferovic, Peter van der Meer, Maurizio Volterrani, Andrew J. Coats, Vijay K. Chopra, Giuseppe Rosano   +25 more
wiley   +1 more source